Max Robotics — Global Service Robot Directory + US Certification

About

Anthony Zeitouni is a leading surgical oncologist whose research focuses on deintensifying treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC), a rapidly growing cancer type. His major contributions center on evaluating neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) as a strategy to reduce treatment-related toxicities while maintaining excellent oncologic outcomes. In his highly cited 2023 study (13 citations), Zeitouni demonstrated that this combined approach significantly improves quality of life by minimizing the need for high-dose radiation and chemotherapy. His 2024 follow-up (10 citations) addressed the critical challenge of distant metastasis, showing that neoadjuvant chemotherapy plus TORS can effectively control systemic spread while lowering adverse effects. This work is pivotal in shifting treatment paradigms for HPV-OPSCC, offering patients a less debilitating path to cure. Zeitouni’s research has been instrumental in advancing organ-preserving, function-sparing therapies, making him a key figure in head and neck cancer care. His findings are widely cited by clinicians and researchers seeking to optimize outcomes for this patient population.